All News

patient.safety.jpg

ICYMI: JAK Inhibitor Misses Endpoint in Safety Study. Now What?

MedPage Today

Pfizer announced results Wednesday from its FDA-mandated postmarketing safety study of tofacitinib (Xeljanz), and they don't bode well for the drug and possibly others in its class.

Read Article
infusion.biologic.jpg

ACR Stands Against Insurer Mandated Infusion Locations

ACR

The American College of Rheumatology (ACR) has released an updated position statement on patient safety and site of service for biologics outlining several reasons why the ACR strongly believes infusions should be administered in a monitored health care setting with onsite supervision by a provid

Read Article
RheumNow Podcast square

RheumNow Podcast – Modern Treatment of RA Pregnancy (6.25.2021)

Jack Cush, MD

Dr. Jack Cush reviews this week’s news and journal reports featured on RheumNow.com.

Read Article
PSA2L.jpg

Progression from Psoriasis to Psoriatic Arthritis

Jack Cush, MD

The question of whether psoriasis is a state or pre-clinical psoriatic arthritis has been addressed by several studies; with one suggesting that biologic use in psoriasis may aver the future development of psoratic arthritis (PsA).

Read Article
pso.arm_.JPG

Which patients with psoriasis are at risk to develop PsA?

Paul Studenic, MD, PhD

The potential transition from psoriasis (PsO) to psoriatic arthritis (PsA) has not been a strong focus for several years but is gaining momentum.

Read Article
meeting.audience.3.jpg

EULAR 2021 – Day 4 Report

Jack Cush, MD

It's been nearly two weeks since EULAR 21 ended. There were several presentations on the last day; notably, the late breaking abstracts and others. Here are a few of my favorites from Day 4, the final day of the meeting.

Read Article
artificial intelligence machine learning computer

Artificial intelligence brings clarity to early bony changes in inflammatory arthritis

David Liew, FRACP

Subtle early bony changes in inflammatory arthritis can be hard even for experienced rheumatologists to interpret, even though they have traditionally been considered to become disease-defining as they progress.

Read Article
depression oh no HA

Psoriatic arthritis mortality & morbidities

Paul Studenic, MD, PhD

Psoriatic arthritis (PsA) is a chronic condition with manifold clinical presentations. Health issues may be far beyond the classical associated conditions like uveitis, enthesitis etc. The current study of Tillett et al (OP0231) assessed comorbidities and patient characteristics comparing psoriasis patients with or without PsA.

Read Article
Psoriasis has greatest risk of MTX liver dz - a Danish Population study of PsO, PsA & RA pts taking MTX. Risk of liver Dz was most in PsO, followed by PsA, then RA. PsO had 1.6-3.4 fold risk (mild-severe) liver dz (vs RA). PsA was 1.3-1.6x higher) https://t.co/pAo9KFr5fO

Links:

Dr. John Cush RheumNow ( View Tweet)

Stroke risk is increased in arthritis (RR 1.36, 95% CI: 1.27–1.46); esp for RA (RR 1.38), AS (RR 1.49), PsA (1.33) & gout (1.40); but NOT osteoarthritis (RR=1.03). Apparently Inflammation drives this risk. https://t.co/Snb6OrtZJH

Links:

Dr. John Cush RheumNow ( View Tweet)

Alcohol abuse worsens psoriasis. Prospective study of 266 Psoriasis pts (1/2 biologics; 1/2 ; conventional Rx). Poorer outcomes predicted by alcohol abuse (CAGE score) (regression co-efficient 1.40), obesity (1.84) & conventional Rx (4.39) https://t.co/CJGTT0HoV2

Links:

Dr. John Cush RheumNow ( View Tweet)

Which patients with psoriasis are at risk to develop PsA? https://t.co/5sj5HSnke3 https://t.co/vxOHIUrevd

Links:

Dr. John Cush RheumNow ( View Tweet)
The FDA has informed Abbvie that their supplemental application for new indications (PsA and AS) for upadacitinib (Rinvoq) has been delayed; the FDA citing its ongoing review of tofacitinibs safety concerns stemming from the ORAL Surveillance RA study https://t.co/sSJyVtQNYu

Links:

Dr. John Cush RheumNow ( View Tweet)

Mouse model of psoriasis; 10 week exposure of western diet (high sugar & fat) induced dysbiosis and increased skin psoriasis & PsA , with increased IL-17A γδ T cells and helper type 17 cytokines. Treatment w/ Abx reduced IL-23 mediated dz. https://t.co/fTCnYiQ3wL

Links:

Dr. John Cush RheumNow ( View Tweet)

Do gender and racial disparities play a role in PsA patients? https://t.co/SrMcGOIbu4 https://t.co/QKD0VoK6fC

Links:

Dr. John Cush RheumNow ( View Tweet)
What are some predictors of PSA development in psoriasis patients? https://t.co/cPlTEJBK5U https://t.co/il6ajaVvtq

Links:

Dr. John Cush RheumNow ( View Tweet)
Which patients with psoriasis are at risk to develop PsA? The potential transition from psoriasis (PsO) to psoriatic arthritis (PsA) has not been a strong focus for several years but is gaining momentum. https://t.co/5sj5HSnke3 https://t.co/UhRHXQwZfG

Links:

Dr. John Cush RheumNow ( View Tweet)
Ten Things to Tell Patients About Diet and Rheumatic Disease: Dr. Eric Dein ( @ejdein1 ) https://t.co/q2Mc1gLZig https://t.co/iV5JO8m5Sv

Links:

Dr. John Cush RheumNow ( View Tweet)
Psoriatic arthritis (PsA) is a chronic condition with manifold clinical presentations. Health issues may be far beyond the classical associated conditions like uveitis, enthesitis etc. https://t.co/zHfeaiiG93

Links:

Dr. John Cush RheumNow ( View Tweet)

Popular article alert! New GRAPPA 2021 PsO and PsA Treatment Recommendations Dr. Rachel Tate ( @uptoTate ) shares insights from abstract #OP0229 at #EULAR2021. https://t.co/AnHQGA8aKs https://t.co/9Acnzofiu4

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×